Pyronaridine (tetraphosphate)

SKU HY-14749A-100 mg Category Tags , ,

$55$264

Products Details

Product Description

– Pyronaridine tetraphosphate is an orally active Mannich base anti-malarial agent. Pyronaridine tetraphosphate is active against P. falciparum and Echinococcus granulosus infection[1][2].

Web ID

– HY-14749A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C29H44ClN5O18P4

Citations

– Cell Rep. 2021 Apr 6;35(1):108959.|Mbio. 2023 Aug 15;e0158723.

References

– [1]Jun Li, et al. Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections. EBioMedicine. 2020 Apr;54:102711. |[2]Vivas L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 2008 Mar;105(3):222-8.

CAS Number

– 76748-86-2

Molecular Weight

– 910.03

Compound Purity

– 99.94

SMILES

– OC1=C(CN2CCCC2)C=C(NC3=C4N=C(OC)C=CC4=NC5=CC(Cl)=CC=C53)C=C1CN6CCCC6.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O

Clinical Information

– Launched

Research Area

– Infection

Solubility

– DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 25 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– Parasite

Isoform

– Plasmodium

Pathway

– Anti-infection

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=